SALAGEN TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PILOCARPINE HYDROCHLORIDE

から入手可能:

AMDIPHARM LIMITED

ATCコード:

N07AX01

INN（国際名）:

PILOCARPINE

投薬量:

5MG

医薬品形態:

TABLET

構図:

PILOCARPINE HYDROCHLORIDE 5MG

投与経路:

ORAL

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

治療領域:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

製品概要:

Active ingredient group (AIG) number: 0107358009; AHFS:

認証ステータス:

APPROVED

承認日:

2003-09-02

製品の特徴

_SALAGEN Product Monograph _
_Page 1 of 33 _
PRODUCT MONOGRAPH
PR
SALAGEN
®
PILOCARPINE HYDROCHLORIDE TABLETS
CHOLINOMIMETIC AGENT
Amdipharm Limited
3 Burlington Road
Dublin 4,
Ireland
DATE OF REVISION:
February
28, 2020
Distributed by:
Methapharm Inc.
81 Sinclair Boulevard
Brantford, Ontario
N3S 7X6
Submission Control No:
235967
® Registered trademark of Mercury Pharma Group Limited, used under
License Amdipharm Limited
_SALAGEN Product Monograph _
_Page 2 of 33 _
Table of Contents
PA RT I: HEALTH PROFESSIONAL INFORMATION
........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................19
PHARMACEUTICAL INFORMATION
..........................................................................19
CLINICAL TRIALS
...............